Developer docs
API playgroundTry for free, no card

Search company profiles

SYLENTIS

Full company profile

uuid0002oc6

Namestring
SYLENTIS
Legal namestring
Sylentis, S.A., Sociedad Unipersonal
Websiteurl
sylentis.com
Company typeenum
Private
Founded yearint
2006
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMadrid, Spain
HQ citystring
Madrid
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNAi therapeutics, ophthalmic drugs, gene silencing, siRNA design, oligonucleotide CDMO
Industry2 codes
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
RNAi-based Ophthalmic Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Licensing
TypeLicensing Royalties
Description

Developing proprietary RNAi-based drugs for ophthalmological diseases. Revenue generated through licensing agreements, co-development deals, and eventual product commercialization. Currently has products in Phase III (tivanisiran) and Phase II (SYL1801) clinical trials.

sylentis.com
2CDMO Services
TypeProfessional Services
Description

Provides specific and customized services for development of RNAi-based compounds for a wide range of targets and oligonucleotide-based drug development for new or existing therapies. Services offered to pharmaceutical and biopharmaceutical companies.

sylentis.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sylentis is a clinical-stage biopharmaceutical company that develops siRNA-based ophthalmic drugs using RNA interference (RNAi) gene silencing technology. Its core pipeline comprises Tivanisiran (SYL1001) eye drops in Phase III for dry eye disease and SYL1801 in Phase II for wet age-related macular degeneration. The company also offers proprietary SirFinder™ AI software for siRNA design and CDMO services for oligonucleotide manufacturing to third-party pharma and biotech clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase III HELIX trial showed improvement (p=0.035) in reduction of central corneal staining for dry eye disease treatment
+3 more records
Product overview1 text field

Sylentis is a biopharmaceutical company specializing in ocular gene silencing using RNAi technology. The core offering consists of SirFinder™, an AI-powered siRNA design platform that enables rapid drug discovery, complemented by a pipeline of siRNA-based therapeutics. The product portfolio includes Tivanisiran (SYL1001) for dry eye disease in Phase 3, SYL1801 for age-related macular degeneration in Phase 2, and earlier-stage candidates for ocular allergies and retinitis pigmentosa. The company also offers CDMO services for oligonucleotide manufacturing.

Product and service4 records
1Tivanisiran (SYL1001)
CategoryOphthalmic siRNA therapeutic
Description

A small interfering RNA (siRNA) administered as eye drops for the treatment of Dry Eye Disease. Inhibits the synthesis of Transient Receptor Potential Vanilloid-1 (TRPV1), targeting both ocular pain detection and innate inflammatory response. Currently in Phase III clinical development.

2SYL1801
CategoryOphthalmic siRNA therapeutic
Description

A chemically modified siRNA administered as eye drops for the prevention and control of wet age-related macular degeneration (AMD). Targets Nrarp to control neovascularization in the retina, offering a non-invasive alternative to intravitreal injections. Currently in Phase II clinical development.

3SirFinder™
CategoryAI drug discovery software
Description

Proprietary AI-based software platform that designs siRNA compounds using mathematical algorithms, neural networks, SVM, and machine learning to identify appropriate mRNA sequences with high silencing efficiency and specificity. Reduces candidate screening work from several years to just weeks. Offered for licensing and as part of partnership engagements.

4CDMO Services
CategoryOligonucleotide CDMO services
Description

Contract Development and Manufacturing Organization services for RNAi-based compound development and oligonucleotide-based drug development for new or existing therapies. Provides customized services for pharmaceutical and biopharmaceutical companies seeking siRNA development and GMP manufacturing expertise.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1IPCEI Med4Cure Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-28
Description

SYOLIGO project is part of IPCEI Med4Cure approved on May 28, 2024, comprising 14 sub-projects led by 13 companies and 11 associated partners from Belgium, Spain, France, Italy, and others, plus 175 indirect partners. Sylentis is the only Spanish company selected as direct participant. Project focuses on sustainable development and manufacturing of RNA-based therapies for rare diseases in Spain and Europe.

sylentis.com
2OLIGOFASTX Consortium
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multidisciplinary consortium comprising Sylentis (PharmaMar Group), Nanovex (Química del Nalón Industrial Group), and five SMEs (AptusBiotech, AptaTargets, Arthex, Nostrum Biodiscovery, Biotechnology Development for Industry in Pharmaceutical). Creates a comprehensive platform for accelerated development of oligonucleotide-based therapies in Spain. Funded by CDTI with €5.4 million.

sylentis.com
3MAAVi Innovation Center (Kimitec)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with MAAVi Innovation Center to develop natural interference RNA molecules for pest and disease control to improve crop yield. Contributes revolutionary science to agriculture sector applications of RNAi technology.

sylentis.com
4SECREted Project Partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Project exploiting Synthetic and Systems Biology tools and aquatic biotechnology for developing new hybrid compounds for agrochemical, pharmaceutical, cosmetic and chemical sectors. Reverse-engineers biosynthetic pathways of extremophile and marine microorganisms.

sylentis.com
5AgrarIA Consortium
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Consortium of 23 public-private organizations investigating Artificial Intelligence as backbone technology for transformation of Spanish agri-food sector value chain. Funded by Ministry of Digital Transformation and European Union NextGenerationEU.

sylentis.com
6Academic and Research Institutions
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Network of collaborators including research centers, national and international universities along with public or private centers for drug development. Supports the company's interdisciplinary approach to RNAi therapeutics research.

sylentis.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

Clinical-stage RNA therapeutics company developing Axiomer® RNA editing technology for inherited retinal diseases including Leber congenital amaurosis and retinitis pigmentosa. Most directly comparable peer — also a mid-sized European-listed company using RNA-based approaches exclusively targeting ophthalmology indications.

TypeBroad incumbent
Description

Larger, NASDAQ-listed siRNA platform company with a broad pipeline including ophthalmology candidates (e.g., ARO-LPA, ARO-C3). Comparable to Sylentis as a siRNA-based therapeutic developer, though substantially larger and more diversified across therapeutic areas.

TypeBroad incumbent
Description

The leading commercial-stage siRNA therapeutics company (Onpattro, Givlaari, Oxlumo, Amvuttra). Has granted Sylentis a technology option license, indicating direct engagement with Sylentis's platform and providing an incumbent benchmark for siRNA commercialization.

TypeBroad incumbent
Description

Established antisense oligonucleotide (ASO) therapeutics company with multiple approved products. A broader RNA-targeting incumbent with adjacent (not identical) technology to Sylentis's siRNA approach and a similar emphasis on rare and ophthalmology indications.

TypeEmerging player
Description

Clinical-stage RNA medicines company developing mRNA, siRNA, and LUNAR® delivery platforms. Comparable as a mid-cap RNA therapeutics developer pursuing ophthalmology and rare disease applications alongside vaccine programs.

TypeEmerging player
Description

Clinical-stage RNA therapeutics company using PRISM® platform for stereopure oligonucleotide design. Comparable to Sylentis as a smaller-cap RNA therapeutics developer targeting rare genetic diseases, including ophthalmology indications.

7SparingVision
TypeEmerging player
Description

European clinical-stage ophthalmology gene therapy company focused on retinal diseases including retinitis pigmentosa. Comparable to Sylentis as a Europe-based, mid-sized biotech developing novel genetic medicines for inherited retinal disorders.

TypeEmerging player
Description

Clinical-stage RNAi-based immuno-oncology therapeutics developer using self-delivering RNAi (sd-rxRNA®) platform. Comparable to Sylentis as a small-cap RNAi platform company, though focused on oncology rather than ophthalmology.

TypeEmerging player
Description

Early-stage RNA editing company developing therapies for neurological, neuromuscular, and ophthalmology diseases including Stargardt disease. Comparable to Sylentis as a next-generation RNA therapeutics company with explicit ophthalmology focus.

10Nitto Denko Avecia
TypeOthers
Description

Leading oligonucleotide CDMO providing contract manufacturing and development services for RNA-based therapeutics including siRNA. Comparable to Sylentis's CDMO service line as an established commercial-scale oligonucleotide manufacturing competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SYLENTIS

RNAi-based Ophthalmic Therapeuticssylentis.com

SYLENTIS firmographics

Firmographics
Name
SYLENTIS
Legal name
Sylentis, S.A., Sociedad Unipersonal
Website
https://sylentis.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

SYLENTIS industry classification

Industry
Product category
RNAi-based Ophthalmic Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • RNAi therapeutics
  • Ophthalmic drugs
  • Gene silencing
  • SiRNA design
  • Oligonucleotide CDMO

Where SYLENTIS is headquartered

Location

Headquarters

HQ city
Madrid
HQ country
Spain
HQ region
Europe

Offices3 records

Markets served

SYLENTIS business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Drug Development and Licensing: Developing proprietary RNAi-based drugs for ophthalmological diseases. Revenue generated through licensing agreements, co-development deals, and eventual product commercialization. Currently has products in Phase III (tivanisiran) and Phase II (SYL1801) clinical trials.
  2. CDMO Services: Provides specific and customized services for development of RNAi-based compounds for a wide range of targets and oligonucleotide-based drug development for new or existing therapies. Services offered to pharmaceutical and biopharmaceutical companies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

SYLENTIS product offering

Product offering

Core offering

Sylentis is a clinical-stage biopharmaceutical company that develops siRNA-based ophthalmic drugs using RNA interference (RNAi) gene silencing technology. Its core pipeline comprises Tivanisiran (SYL1001) eye drops in Phase III for dry eye disease and SYL1801 in Phase II for wet age-related macular degeneration. The company also offers proprietary SirFinder™ AI software for siRNA design and CDMO services for oligonucleotide manufacturing to third-party pharma and biotech clients.

Product overview

Sylentis is a biopharmaceutical company specializing in ocular gene silencing using RNAi technology. The core offering consists of SirFinder™, an AI-powered siRNA design platform that enables rapid drug discovery, complemented by a pipeline of siRNA-based therapeutics. The product portfolio includes Tivanisiran (SYL1001) for dry eye disease in Phase 3, SYL1801 for age-related macular degeneration in Phase 2, and earlier-stage candidates for ocular allergies and retinitis pigmentosa. The company also offers CDMO services for oligonucleotide manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tivanisiran (SYL1001) A small interfering RNA (siRNA) administered as eye drops for the treatment of Dry Eye Disease. Inhibits the synthesis of Transient Receptor Potential Vanilloid-1 (TRPV1), targeting both ocular pain detection and innate inflammatory response. Currently in Phase III clinical development.
  • SYL1801 A chemically modified siRNA administered as eye drops for the prevention and control of wet age-related macular degeneration (AMD). Targets Nrarp to control neovascularization in the retina, offering a non-invasive alternative to intravitreal injections. Currently in Phase II clinical development.
  • SirFinder™ Proprietary AI-based software platform that designs siRNA compounds using mathematical algorithms, neural networks, SVM, and machine learning to identify appropriate mRNA sequences with high silencing efficiency and specificity. Reduces candidate screening work from several years to just weeks. Offered for licensing and as part of partnership engagements.
  • CDMO Services Contract Development and Manufacturing Organization services for RNAi-based compound development and oligonucleotide-based drug development for new or existing therapies. Provides customized services for pharmaceutical and biopharmaceutical companies seeking siRNA development and GMP manufacturing expertise.

Quantifiable outcome

  • Phase III HELIX trial showed improvement (p=0.035) in reduction of central corneal staining for dry eye disease treatment
  • +3 more outcomes

Companies that use SYLENTIS

Customer profile

Segments3 records

Ideal customer profiles1 record

SYLENTIS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

SYLENTIS partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • IPCEI Med4Cure ConsortiumcoreStrategic or Co-development Partner · 28 May 2024SYOLIGO project is part of IPCEI Med4Cure approved on May 28, 2024, comprising 14 sub-projects led by 13 companies and 11 associated partners from Belgium, Spain, France, Italy, and others, plus 175 indirect partners. Sylentis is the only Spanish company selected as direct participant. Project focuses on sustainable development and manufacturing of RNA-based therapies for rare diseases in Spain and Europe.
  • OLIGOFASTX ConsortiumcoreStrategic or Co-development PartnerMultidisciplinary consortium comprising Sylentis (PharmaMar Group), Nanovex (Química del Nalón Industrial Group), and five SMEs (AptusBiotech, AptaTargets, Arthex, Nostrum Biodiscovery, Biotechnology Development for Industry in Pharmaceutical). Creates a comprehensive platform for accelerated development of oligonucleotide-based therapies in Spain. Funded by CDTI with €5.4 million.
  • MAAVi Innovation Center (Kimitec)minorStrategic or Co-development PartnerCollaboration with MAAVi Innovation Center to develop natural interference RNA molecules for pest and disease control to improve crop yield. Contributes revolutionary science to agriculture sector applications of RNAi technology.
  • SECREted Project PartnersminorStrategic or Co-development PartnerProject exploiting Synthetic and Systems Biology tools and aquatic biotechnology for developing new hybrid compounds for agrochemical, pharmaceutical, cosmetic and chemical sectors. Reverse-engineers biosynthetic pathways of extremophile and marine microorganisms.
  • AgrarIA ConsortiumminorStrategic or Co-development PartnerConsortium of 23 public-private organizations investigating Artificial Intelligence as backbone technology for transformation of Spanish agri-food sector value chain. Funded by Ministry of Digital Transformation and European Union NextGenerationEU.
  • Academic and Research InstitutionsminorStrategic or Co-development PartnerNetwork of collaborators including research centers, national and international universities along with public or private centers for drug development. Supports the company's interdisciplinary approach to RNAi therapeutics research.

Scale indicators7 records

Recent moves7 records

SYLENTIS competitors and assessment

Company assessment

Direct peers

  • ProQR Therapeutics: Clinical-stage RNA therapeutics company developing Axiomer® RNA editing technology for inherited retinal diseases including Leber congenital amaurosis and retinitis pigmentosa. Most directly comparable peer — also a mid-sized European-listed company using RNA-based approaches exclusively targeting ophthalmology indications.

Broad incumbents

  • Arrowhead Pharmaceuticals: Larger, NASDAQ-listed siRNA platform company with a broad pipeline including ophthalmology candidates (e.g., ARO-LPA, ARO-C3). Comparable to Sylentis as a siRNA-based therapeutic developer, though substantially larger and more diversified across therapeutic areas.
  • Alnylam Pharmaceuticals: The leading commercial-stage siRNA therapeutics company (Onpattro, Givlaari, Oxlumo, Amvuttra). Has granted Sylentis a technology option license, indicating direct engagement with Sylentis's platform and providing an incumbent benchmark for siRNA commercialization.
  • Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) therapeutics company with multiple approved products. A broader RNA-targeting incumbent with adjacent (not identical) technology to Sylentis's siRNA approach and a similar emphasis on rare and ophthalmology indications.

Emerging players

  • Arcturus Therapeutics: Clinical-stage RNA medicines company developing mRNA, siRNA, and LUNAR® delivery platforms. Comparable as a mid-cap RNA therapeutics developer pursuing ophthalmology and rare disease applications alongside vaccine programs.
  • Wave Life Sciences: Clinical-stage RNA therapeutics company using PRISM® platform for stereopure oligonucleotide design. Comparable to Sylentis as a smaller-cap RNA therapeutics developer targeting rare genetic diseases, including ophthalmology indications.
  • SparingVision: European clinical-stage ophthalmology gene therapy company focused on retinal diseases including retinitis pigmentosa. Comparable to Sylentis as a Europe-based, mid-sized biotech developing novel genetic medicines for inherited retinal disorders.
  • Phio Pharmaceuticals: Clinical-stage RNAi-based immuno-oncology therapeutics developer using self-delivering RNAi (sd-rxRNA®) platform. Comparable to Sylentis as a small-cap RNAi platform company, though focused on oncology rather than ophthalmology.
  • Ascidian Therapeutics: Early-stage RNA editing company developing therapies for neurological, neuromuscular, and ophthalmology diseases including Stargardt disease. Comparable to Sylentis as a next-generation RNA therapeutics company with explicit ophthalmology focus.

Others

  • Nitto Denko Avecia: Leading oligonucleotide CDMO providing contract manufacturing and development services for RNA-based therapeutics including siRNA. Comparable to Sylentis's CDMO service line as an established commercial-scale oligonucleotide manufacturing competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

SYLENTIS social profiles

Digital presence

SYLENTIS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SYLENTIS leadership team

Management profile

Number of profiles

Profiles7 records

SYLENTIS funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SYLENTIS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SYLENTIS

What does SYLENTIS do?

Sylentis is a clinical-stage biopharmaceutical company that develops siRNA-based ophthalmic drugs using RNA interference (RNAi) gene silencing technology. Its core pipeline comprises Tivanisiran (SYL1001) eye drops in Phase III for dry eye disease and SYL1801 in Phase II for wet age-related macular degeneration. The company also offers proprietary SirFinder™ AI software for siRNA design and CDMO services for oligonucleotide manufacturing to third-party pharma and biotech clients.

Is SYLENTIS a public or private company?

SYLENTIS is a private company. It is classified as corporate owned and is currently operating.

When was SYLENTIS founded?

SYLENTIS was founded in 2006. It employs 51 to 100 people.

Where is SYLENTIS based?

SYLENTIS is headquartered in Madrid, Spain, in the Europe region.

How does SYLENTIS make money?

Two revenue lines are on record. Drug Development and Licensing is the primary driver. The others are CDMO Services.

Who are SYLENTIS's main competitors?

ProQR Therapeutics is listed as a direct peer. Broad incumbents are Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals and Ionis Pharmaceuticals. Emerging players are Arcturus Therapeutics, Wave Life Sciences, SparingVision, Phio Pharmaceuticals and Ascidian Therapeutics. Nitto Denko Avecia is listed as an others.

Does SYLENTIS have an API?

No public API is recorded for SYLENTIS.

What industry is SYLENTIS in?

SYLENTIS's product category is RNAi-based Ophthalmic Therapeutics. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSylentis, PharmaMar Group, Announces the End of Patient Recruitment for its HELIX TrialSylentis, a pharmaceutical company within the PharmaMar Group, announced the completion of patient recruitment for its Phase III HELIX trial evaluating tivanisiran for the treatment of dry eye disease, having enrolled 329 patients across 39 centers in six European countries. The trial results are expected in the first four months of 2019, with the primary endpoint measuring the drug's effect on signs and symptoms of dry eye patients for whom therapeutic options are currently limited. The company expressed confidence in its RNA interference technology, positioning tivanisiran as a potential alternative treatment for the estimated 344 million people globally affected by dry eye.PR NewswireSylentis Announces New Data on the Treatment of Allergic ConjunctivitisSylentis, a biotechnology company belonging to the PharmaMar Group, presented preclinical results at the ARVO annual meeting in Honolulu for its RNAi therapy candidate SYL116011, designed to treat seasonal ocular allergies caused by pollen. The results demonstrated that the treatment reduces allergy-related symptoms such as swelling and tearing by 50% to 80%, and is administered once daily with fewer side effects compared to standard antihistamines that require three to four daily doses. The company is a leader in RNAi technology and has multiple therapeutic candidates in clinical development phases for ophthalmological conditions including glaucoma and ocular pain.PR NewswireSylentis Presented New Results for the Treatment of Age Associated Macular DegenerationSylentis, a biotechnology company owned by PharmaMar Group, presented preclinical results for SYL1801, a new topical molecule targeting age-related macular degeneration, at the ARVO annual meeting in Honolulu. The treatment candidate works by silencing the NRARP protein to inhibit neovascularization in the retina, potentially offering a non-invasive alternative to current intravitreal injections. Sylentis, a pioneer in RNAi technology applied to ophthalmology, continues advancing its pipeline which includes additional candidates in Phase II and III studies for glaucoma and ocular pain.PR NewswireSylentis Announces the Clinical Results of Tivanisiran for the Treatment of Dry Eye SyndromeSylentis, a subsidiary of PharmaMar, announced positive clinical results for tivanisiran in treating dry eye syndrome, leading to the initiation of the Phase III "Helix" trial. The study involves 300 patients across six European countries to evaluate the drug's efficacy in reducing ocular pain and improving tear quality. This development marks a significant step forward in applying RNA interference technology to ophthalmology.PR NewswireSylentis Presents New Results on Its Ophthalmological Compounds at ARVO 2018Sylentis, a pharmaceutical company owned by PharmaMar Group, presented new clinical results for three ophthalmological compounds at the ARVO 2018 annual meeting in Honolulu. The presentations covered treatments for dry eye syndrome, age-related macular degeneration, and eye allergies using RNA interference technology. This activity highlights Sylentis's progress in developing topical siRNA therapies for these specific conditions.PR NewswireErste Patienten mit dem Syndrom des Trockenen Auges in Phase III Studie HELIX in Deutschland rekrutiertSylentis announced the recruitment of the first patients in Germany for its Phase III HELIX clinical trial evaluating Tivanisiran (SYL1001) for dry eye syndrome. The multinational study involves over 30 hospitals across six European countries and aims to assess the drug's efficacy in treating symptoms in 300 patients. This development marks a key step toward seeking regulatory approval for the RNAi-based therapy.PR NewswirePharmaMar: Sylentis Presents New Data on a New Eye Drop siRNA for the Treatment of Retinal Diseases Avoiding Intraocular InjectionsPharmaMar subsidiary Sylentis presented positive efficacy data on SYL136001v10, an siRNA-based eye drop treatment for neovascular retinal diseases such as age-related macular degeneration and diabetic retinopathy. The treatment demonstrated it can reach the retina topically, potentially eliminating the need for painful intraocular anti-VEGF injections that currently require hospital administration. The findings were presented at the XIII Annual Meeting of the Oligonucleotide Therapeutics Society in Bordeaux, France.PR NewswirePharmaMar : Sylentis présente de nouvelles données sur un nouveau pARNi à usage topique pour le traitement des maladies de la rétine évitant les injections intraoculairesSylentis, a subsidiary of PharmaMar, presented positive preclinical data on SYL136001v10, a topical pARNi (small interfering RNA) treatment for neovascular retinal diseases including age-related macular degeneration and diabetic retinopathy. The treatment successfully reached the retina when administered as eye drops, demonstrating efficacy equivalent to standard anti-VEGF injections but without the need for intraocular procedures. The findings were presented at the 13th Annual Oligonucleotide Therapeutics Society assembly in Bordeaux, France, suggesting a potential paradigm shift in how these sight-threatening conditions could be managed.PR NewswireA Sylentis Inicia um Estudo de Fase III para Tratamento da Síndrome do Olho SecoPharmaceutical company Sylentis (PharmaMar Group) has initiated its first Phase III clinical trial, HELIX, for the experimental drug SYL1001, an RNA interference-based ophthalmic solution for treating dry eye syndrome. The trial will enroll approximately 300 patients across more than 20 centers in five European countries — Spain, Germany, Estonia, Portugal, and Italy — following an agreement with the U.S. FDA on the clinical program to support a future New Drug Application submission. Dry eye syndrome affects 344 million people worldwide, with risk increasing 35% per decade of life, and the condition is linked to factors such as pollution, air conditioning, contact lens use, and prolonged computer screen exposure.PR NewswireSylentis Initiates a Phase III Study for the Treatment of Dry Eye SyndromePharmaceutical company Sylentis (PharmaMar Group) has initiated the HELIX Phase III clinical trial for its investigational drug SYL1001, an RNA interference-based eye drop treatment for dry eye syndrome, following agreement with the FDA on the clinical program. The multicenter trial will enroll approximately 300 patients across more than 30 centers in five European countries—Spain, Germany, Estonia, Portugal, and Italy—to evaluate improvements in signs and symptoms of dry eye disease. Dry eye syndrome affects approximately 344 million people worldwide, with few therapeutic options currently available, and SYL1001 represents a novel mechanism of action targeting the underlying pathology through gene silencing technology.